Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01367665




Registration number
NCT01367665
Ethics application status
Date submitted
30/05/2011
Date registered
7/06/2011
Date last updated
6/06/2019

Titles & IDs
Public title
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Scientific title
A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)
Secondary ID [1] 0 0
2011-000195-34
Secondary ID [2] 0 0
MO25616
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Basal Cell Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - vismodegib

Experimental: Vismodegib - Locally Advanced - Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity

Experimental: Vismodegib - Metastatic - Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity


Treatment: Drugs: vismodegib
150 mg once daily until disease progression or unacceptable toxicity
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs)
Timepoint [1] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Primary outcome [2] 0 0
Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons
Timepoint [2] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Primary outcome [3] 0 0
Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters
Timepoint [3] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Primary outcome [4] 0 0
Exposure to Study Treatment: Duration on Treatment
Timepoint [4] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Primary outcome [5] 0 0
Exposure to Study Treatment - Dose Intensity
Timepoint [5] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Secondary outcome [1] 0 0
Best Overall Response Rate (BORR)
Timepoint [1] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Secondary outcome [2] 0 0
Duration of Response
Timepoint [2] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Secondary outcome [3] 0 0
Time to Response
Timepoint [3] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Secondary outcome [4] 0 0
Progression-Free Survival (PFS)
Timepoint [4] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Secondary outcome [5] 0 0
Overall Survival (OS)
Timepoint [5] 0 0
Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Secondary outcome [6] 0 0
Change From Baseline Scores of Skindex-16 Questionnaire Domains of Emotion, Function and Symptom
Timepoint [6] 0 0
Baseline to the data cut-off date of 14 June 2017 (up to 6 years).
Secondary outcome [7] 0 0
Percentage of Participants With a = 30% Reduction in Disease-Related Symptoms According to MDASI Scale
Timepoint [7] 0 0
08-May-2013 (Protocol Version = 4) to the data cut-off date of 14 June 2017 (approximately 4 years and 1 month).
Secondary outcome [8] 0 0
Percentage of Participants With a = 30% Reduction in Composite Symptom Severity Score According to MDASI Scale
Timepoint [8] 0 0
08-May-2013 (Protocol Version = 4) to the data cut-off date of 14 June 2017 (approximately 4 years and 1 month).

Eligibility
Key inclusion criteria
* Adult patients, >/=18 years of age
* Metastatic or locally advanced basal cell carcinoma considered inoperable or that surgery is contraindicated and radiotherapy is contraindicated or inappropriate
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Concurrent anti-tumor therapy
* Completion of the most recent anti-tumor therapy less than 21 days prior to the initiation of treatment
* Uncontrolled medical illness

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/06/2017
Sample size
Target
Accrual to date
Final
1232
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Premier Specialists - Kogarah
Recruitment hospital [2] 0 0
Skin and Cancer Foundation Australia - Westmead
Recruitment hospital [3] 0 0
CMAX A division of IDT Australia Limited - Adelaide
Recruitment hospital [4] 0 0
Skin & Cancer Foundation - Carlton
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3053 - Carlton
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Austria
State/province [2] 0 0
Graz
Country [3] 0 0
Austria
State/province [3] 0 0
Salzburg
Country [4] 0 0
Austria
State/province [4] 0 0
St. Pölten
Country [5] 0 0
Austria
State/province [5] 0 0
Wien
Country [6] 0 0
Belgium
State/province [6] 0 0
Leuven
Country [7] 0 0
Bosnia and Herzegovina
State/province [7] 0 0
Banja Luka
Country [8] 0 0
Bosnia and Herzegovina
State/province [8] 0 0
Sarajevo
Country [9] 0 0
Brazil
State/province [9] 0 0
RS
Country [10] 0 0
Brazil
State/province [10] 0 0
SP
Country [11] 0 0
Bulgaria
State/province [11] 0 0
Plovdiv
Country [12] 0 0
Bulgaria
State/province [12] 0 0
Sofia
Country [13] 0 0
Canada
State/province [13] 0 0
Alberta
Country [14] 0 0
Canada
State/province [14] 0 0
Manitoba
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
Canada
State/province [16] 0 0
Quebec
Country [17] 0 0
Colombia
State/province [17] 0 0
Bogota
Country [18] 0 0
Colombia
State/province [18] 0 0
Cali
Country [19] 0 0
Colombia
State/province [19] 0 0
Medellin-Antioquia
Country [20] 0 0
Colombia
State/province [20] 0 0
Medellin
Country [21] 0 0
Croatia
State/province [21] 0 0
Zagreb
Country [22] 0 0
Czechia
State/province [22] 0 0
Ceske Budejovice
Country [23] 0 0
Czechia
State/province [23] 0 0
Hradec Kralove
Country [24] 0 0
Czechia
State/province [24] 0 0
Ostrava
Country [25] 0 0
Czechia
State/province [25] 0 0
Praha 2
Country [26] 0 0
Czechia
State/province [26] 0 0
Praha 5
Country [27] 0 0
Czechia
State/province [27] 0 0
Praha
Country [28] 0 0
Denmark
State/province [28] 0 0
Herlev
Country [29] 0 0
Finland
State/province [29] 0 0
Helsinki
Country [30] 0 0
Finland
State/province [30] 0 0
Kuopio
Country [31] 0 0
France
State/province [31] 0 0
Bordeaux
Country [32] 0 0
France
State/province [32] 0 0
Boulogne-billancourt
Country [33] 0 0
France
State/province [33] 0 0
Dijon
Country [34] 0 0
France
State/province [34] 0 0
Lille
Country [35] 0 0
France
State/province [35] 0 0
Marseille
Country [36] 0 0
France
State/province [36] 0 0
Montpellier
Country [37] 0 0
France
State/province [37] 0 0
Nantes
Country [38] 0 0
France
State/province [38] 0 0
Paris
Country [39] 0 0
France
State/province [39] 0 0
Pierre Benite
Country [40] 0 0
France
State/province [40] 0 0
Toulouse
Country [41] 0 0
France
State/province [41] 0 0
Villejuif
Country [42] 0 0
Germany
State/province [42] 0 0
Berlin
Country [43] 0 0
Germany
State/province [43] 0 0
Buxtehude
Country [44] 0 0
Germany
State/province [44] 0 0
Dortmund
Country [45] 0 0
Germany
State/province [45] 0 0
Dresden
Country [46] 0 0
Germany
State/province [46] 0 0
Düsseldorf
Country [47] 0 0
Germany
State/province [47] 0 0
Erfurt
Country [48] 0 0
Germany
State/province [48] 0 0
Essen
Country [49] 0 0
Germany
State/province [49] 0 0
Frankfurt
Country [50] 0 0
Germany
State/province [50] 0 0
Freiburg
Country [51] 0 0
Germany
State/province [51] 0 0
Greifswald
Country [52] 0 0
Germany
State/province [52] 0 0
Hamburg
Country [53] 0 0
Germany
State/province [53] 0 0
Hannover
Country [54] 0 0
Germany
State/province [54] 0 0
Heidelberg
Country [55] 0 0
Germany
State/province [55] 0 0
Heilbronn
Country [56] 0 0
Germany
State/province [56] 0 0
Kassel
Country [57] 0 0
Germany
State/province [57] 0 0
Kiel
Country [58] 0 0
Germany
State/province [58] 0 0
Köln
Country [59] 0 0
Germany
State/province [59] 0 0
Ludwigshafen
Country [60] 0 0
Germany
State/province [60] 0 0
Lübeck
Country [61] 0 0
Germany
State/province [61] 0 0
Magdeburg
Country [62] 0 0
Germany
State/province [62] 0 0
Mannheim
Country [63] 0 0
Germany
State/province [63] 0 0
Marburg
Country [64] 0 0
Germany
State/province [64] 0 0
Muenster
Country [65] 0 0
Germany
State/province [65] 0 0
München
Country [66] 0 0
Germany
State/province [66] 0 0
Nürnberg
Country [67] 0 0
Germany
State/province [67] 0 0
Quedlinburg
Country [68] 0 0
Germany
State/province [68] 0 0
Regensburg
Country [69] 0 0
Germany
State/province [69] 0 0
Tübingen
Country [70] 0 0
Germany
State/province [70] 0 0
Würzburg
Country [71] 0 0
Greece
State/province [71] 0 0
Athens
Country [72] 0 0
Greece
State/province [72] 0 0
Heraklion
Country [73] 0 0
Greece
State/province [73] 0 0
Ioannina
Country [74] 0 0
Greece
State/province [74] 0 0
Thessaloniki
Country [75] 0 0
Hungary
State/province [75] 0 0
Budapest
Country [76] 0 0
Hungary
State/province [76] 0 0
Debrecen
Country [77] 0 0
Hungary
State/province [77] 0 0
Kaposvár
Country [78] 0 0
Hungary
State/province [78] 0 0
Szeged
Country [79] 0 0
Ireland
State/province [79] 0 0
Cork
Country [80] 0 0
Ireland
State/province [80] 0 0
Dublin
Country [81] 0 0
Israel
State/province [81] 0 0
Halfa
Country [82] 0 0
Israel
State/province [82] 0 0
Jerusalem
Country [83] 0 0
Israel
State/province [83] 0 0
Petach Tikva
Country [84] 0 0
Israel
State/province [84] 0 0
Ramat Gan
Country [85] 0 0
Italy
State/province [85] 0 0
Abruzzo
Country [86] 0 0
Italy
State/province [86] 0 0
Campania
Country [87] 0 0
Italy
State/province [87] 0 0
Emilia-Romagna
Country [88] 0 0
Italy
State/province [88] 0 0
Lazio
Country [89] 0 0
Italy
State/province [89] 0 0
Liguria
Country [90] 0 0
Italy
State/province [90] 0 0
Lombardia
Country [91] 0 0
Italy
State/province [91] 0 0
Marche
Country [92] 0 0
Italy
State/province [92] 0 0
Piemonte
Country [93] 0 0
Italy
State/province [93] 0 0
Puglia
Country [94] 0 0
Italy
State/province [94] 0 0
Sardegna
Country [95] 0 0
Italy
State/province [95] 0 0
Toscana
Country [96] 0 0
Italy
State/province [96] 0 0
Veneto
Country [97] 0 0
Lithuania
State/province [97] 0 0
Vilnius
Country [98] 0 0
Mexico
State/province [98] 0 0
Mexico CITY (federal District)
Country [99] 0 0
Netherlands
State/province [99] 0 0
Groningen
Country [100] 0 0
Netherlands
State/province [100] 0 0
Leiden
Country [101] 0 0
Netherlands
State/province [101] 0 0
Maastricht
Country [102] 0 0
Netherlands
State/province [102] 0 0
Rotterdam
Country [103] 0 0
New Zealand
State/province [103] 0 0
Takapuna
Country [104] 0 0
Norway
State/province [104] 0 0
Oslo
Country [105] 0 0
Poland
State/province [105] 0 0
Gdansk
Country [106] 0 0
Poland
State/province [106] 0 0
Lodz
Country [107] 0 0
Poland
State/province [107] 0 0
Poznan
Country [108] 0 0
Poland
State/province [108] 0 0
Warsaw
Country [109] 0 0
Portugal
State/province [109] 0 0
Porto
Country [110] 0 0
Romania
State/province [110] 0 0
Bucuresti
Country [111] 0 0
Romania
State/province [111] 0 0
Cluj Napoca
Country [112] 0 0
Romania
State/province [112] 0 0
Craiova
Country [113] 0 0
Romania
State/province [113] 0 0
Targu Mures
Country [114] 0 0
Romania
State/province [114] 0 0
Timisoara
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Leningrad
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Moscow
Country [117] 0 0
Russian Federation
State/province [117] 0 0
St Petersburg
Country [118] 0 0
Serbia
State/province [118] 0 0
Belgrade
Country [119] 0 0
Slovakia
State/province [119] 0 0
Banska Bystrica
Country [120] 0 0
Slovenia
State/province [120] 0 0
Ljubljana
Country [121] 0 0
Spain
State/province [121] 0 0
Asturias
Country [122] 0 0
Spain
State/province [122] 0 0
Islas Baleares
Country [123] 0 0
Spain
State/province [123] 0 0
LAS Palmas
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Spain
State/province [125] 0 0
Navarra
Country [126] 0 0
Spain
State/province [126] 0 0
Tenerife
Country [127] 0 0
Spain
State/province [127] 0 0
Vizcaya
Country [128] 0 0
Spain
State/province [128] 0 0
Barcelona
Country [129] 0 0
Spain
State/province [129] 0 0
Cordoba
Country [130] 0 0
Spain
State/province [130] 0 0
Granada
Country [131] 0 0
Spain
State/province [131] 0 0
Guadalajara
Country [132] 0 0
Spain
State/province [132] 0 0
Leon
Country [133] 0 0
Spain
State/province [133] 0 0
Murcia
Country [134] 0 0
Spain
State/province [134] 0 0
Sevilla
Country [135] 0 0
Spain
State/province [135] 0 0
Toledo
Country [136] 0 0
Spain
State/province [136] 0 0
Valencia
Country [137] 0 0
Spain
State/province [137] 0 0
Zaragoza
Country [138] 0 0
Sweden
State/province [138] 0 0
Lund
Country [139] 0 0
Sweden
State/province [139] 0 0
Stockholm
Country [140] 0 0
Switzerland
State/province [140] 0 0
Zürich
Country [141] 0 0
Turkey
State/province [141] 0 0
Ankara
Country [142] 0 0
Turkey
State/province [142] 0 0
Istanbul
Country [143] 0 0
Turkey
State/province [143] 0 0
Izmir
Country [144] 0 0
Turkey
State/province [144] 0 0
Sihhiye, Ankara
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Cambridge
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Glasgow
Country [147] 0 0
United Kingdom
State/province [147] 0 0
London
Country [148] 0 0
United Kingdom
State/province [148] 0 0
New Castle Upon Tyne
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Salford
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01367665